Scinai Immunotherapeutics Ltd. (SCNI)
| Previous close | 0.4396 |
| Open | 0.4459 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.4400 - 0.4459 |
| 52-week range | 0.4310 - 2.2700 |
| Volume | |
| Avg. volume | 27,081 |
| Market cap | 1.915M |
| Beta (5Y monthly) | 2.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.4000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireScinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that the company's Chief Science Officer, Dr. Tamar Ben-Yedidia, and the University Medical Center Göttingen's Director, Department of Dermatology, Venereology & Allergology, Prof. Michael Schön, will be presenting together at the upcoming 5th Dermatology
- PR Newswire
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that Ayana Pharma Ltd. signed a five-year Master Service Agreement (MSA) with the Company's CDMO business unit, Scinai Bioservices.
- PR Newswire
Scinai leadership to attend BIO-Europe Spring 2024
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it will be participating in partnership meetings and exhibiting its CDMO services at the BIO-Europe Spring 2024 conference, taking place March 18 to 20 in Barcelona.
